Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual.
Por:
Pichini S, Mannocchi G, Gottardi M, Pérez-Acevedo AP, Poyatos L, Papaseit E, Pérez-Mañá C, Farré M, Pacifici R and Busardò FP
Publicada:
1 mar 2020
Ahead of Print:
15 nov 2019
Resumen:
Monitoring pharmacological active compounds in pharmaceutical preparations of medical cannabis and in conventional and non-conventional biological matrices of treated individuals use requires both a wide linear range and sensitive detection. We have developed and validated a fast and sensitive method using ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) for analysis of -9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors -9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA) and some major metabolites of THC such as 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy-THC (11-OH-THC), -9-THC-Glucuronide (THC-GLUC) and THC-COOH-Glucuronide (THC-COOH-GLUC) in conventional (whole blood and urine) and non-conventional (oral fluid and sweat) of individual treated with medical cannabis preparation. Specifically, THC, THCA-A, CBD and CBD-A were determined in cannabis decoction and oil prepared to treat individuals. The method used positive electrospray ionization (ESI) mode to reach the sensitivity needed to detect minimal amounts of analytes under investigations exposure with limits of quantification ranging from 0.2 to 0.5 ng per milliliter (ng/mL) or ng per patch in case of collected sweat. The validation results indicated this method was accurate (average inter/intra-day error, <10%), precise (inter/intra-day imprecision, <10%), and fast (10 min run time). In addition, time-consuming sample preparation was avoided applying dilute and shoot procedure, meeting the needs for potential large-scale population studies. The analysis of real samples demonstrated a pharmacokinetics of cannabinoids, their precursors and their metabolites dependent from quantity of carboxylated and decarboxylated compounds in pharmaceutical preparations.
Filiaciones:
Pichini S:
National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy
Mannocchi G:
University of Camerino, Camerino, Italy
Gottardi M:
Comedical S.rL, Trento, Italy
Pérez-Acevedo AP:
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTiP-IGTP, Badalona, Spain
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Cerdantola del Vallés, Spain
:
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTiP-IGTP, Badalona, Spain
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Cerdantola del Vallés, Spain
:
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTiP-IGTP, Badalona, Spain
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Cerdantola del Vallés, Spain
:
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTiP-IGTP, Badalona, Spain
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Cerdantola del Vallés, Spain
:
Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTiP-IGTP, Badalona, Spain
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Cerdantola del Vallés, Spain
Pacifici R:
National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy
Busardò FP:
Department of Excellence-Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy
|